feedback

Course Director

Naiyer Rizvi, MD
Naiyer Rizvi, MD

Columbia University Medical Center
New York, New York

Faculty

Benny Weksler
Benny Weksler, MBA, MD

Allegheny Health Network
Pittsburgh, Pennsylvania

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CE
Credit Amount:1.0 Credits
Release Date:2018-Dec-14
Expiration Date:2019-Dec-13
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

New evidence on immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the landscape is constantly changing and checkpoint inhibitor–based therapies are establishing a foothold not only in metastatic disease, but also transitioning into earlier stages of lung cancer. In stage III NSCLC, immunotherapy has become a new standard option as a component of multimodal therapy. Various single-agent and combinatorial approaches are being explored in different settings of early-stage disease. What are the implications of these advances in the lung cancer treatment arsenal for thoracic surgeons?

During an engaging MasterClass and Practicum educational session, a thoracic surgeon and an oncologist focus on this question. They review the rationale for and latest evidence on using immunotherapies in the management of patients with earlier stages of lung cancer and debate the practicalities, as well as key challenges and controversies, related to optimal integration of this therapeutic approach into clinical practice.

Upon completion of this activity, participants will be able to:
  • Describe current evidence on the interactions between cancer and immunity, the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer
  • Summarize the present immunotherapy landscape and state of the science in lung cancer, including key approvals/indications in different settings from early-stage to more advanced disease
  • Discuss the key clinical trials assessing immunotherapies and immune-based combinations in earlier stages of lung cancer, and the available data from such trials
  • Determine the best treatment approaches for patients with lung cancer in the context of clinical practice or clinical trials based on the latest evidence, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care

Target Audience

The activity will be designed to meet the educational needs of thoracic surgeons, medical oncologists, radiation oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with lung cancer.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 14, 2018 - December 13, 2019
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CE activity during the past 12 months.

Course Director

Naiyer Rizvi, MD
Price Family Chair Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Shareholder in Gritstone Oncology where Dr. Rizvi is a Co-Founder.
Naiyer Rizvi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations.

Faculty

Benny Weksler, MBA, MD
System Chief of Thoracic Surgery
Allegheny Health Network
Pittsburgh, Pennsylvania

Benny Weksler, MBA, MD, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Dr. Weksler is a proctor for Intuitive Surgical Inc.
Benny Weksler, MBA, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations.

CME Reviewer

Siyang Leng, MD

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Janice Trainor-Tellier, MSN, RN

Janice Trainor-Tellier, MSN, RN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

Providership


This CME/MOC/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.